- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04040712
Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors
Fecal Microbiota Transplantation to Treat Diarrhea Induced by Tyrosine-kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma: a Randomized Clinical Trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Despite the improvement in diagnosis and management, renal cell carcinoma (RCC) remains one of the most burdensome urological cancers, being the sixth most common malignancy in men and the 10th in women, accounting, respectively, for 5% and 3% of all cancers. Moreover, the incidence of RCC is increasing, especially in Western countries, accounting for nearly 60000 new cases per year in the United States. A considerable proportion of patients present with metastatic disease at diagnosis, and there are more than 140000 RCC-dependent deaths per year worldwide according to the World Health Organization.
Sunitinib and pazopanib are oral multi-targeted receptor tyrosine kinase inhibitors (TKIs) that have dramatically improved the survival of patients with metastatic RCC, and are commonly used as first-line option for this condition.
However, long-term use of these drugs is prevented by the development of toxicity. Diarrhea is one of the most common side effects of TKIs, occurring in nearly 50% of patients. It decreases the quality of life of these patients, and often requires dose reduction and drug discontinuation, potentially decreasing the efficacy of TKIs.
To date there are no standardized strategies for TKIs-related diarrhea, and current recommendations are supported by few evidence or real-life experience. Recommended treatment options include anti-motility agents, which are not targeted to act on the pathogenic pathways of diarrhea.
Increasing evidence suggests that gut microbiota could influence the development of TKIs-induced diarrhea. Overall, chemotherapy is known to drive, through the development of mucositis, deep compositional and functional alterations of gut microbiota. Mucositis occurs commonly after treatment with TKIs, and a specific dysbiotic profile has been found in patients with TKIs-induced diarrhea.
In theory, the therapeutic modulation of gut microbiota could be an approach to alleviate TKI-induced diarrhea. Although probiotics have been suggested as a possible treatment option for this condition, few evidence supports this indication.
Fecal microbiota transplantation (FMT) is the infusion of fecal microbiota from a healthy donor in the gut of a recipient with the aim of curing a specific disease. It has been increasingly recognized as a highly effective treatment against recurrent Clostridium difficile infection.
FMT has been also examined as a potential approach for other disorders associated with a disruption of gut microbiota, including ulcerative colitis or metabolic syndrome.
To date, the effects of FMT on chemotherapy-related diarrhea are unknown. The aim of this study is to investigate the efficacy of fecal microbiota transplantation (FMT), compared with sham FMT, in treating TKI-induced diarrhea in patients with metastatic RCC
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00168
- Fondazione Policlinico Universitario "A. Gemelli" IRCCS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years old or older
- treatment with pazopanib or sunitinib for metastatic RCC diagnosed at histology and measurable according to RECIST criteria version 1.1
- development of diarrhea of 2-3 grade according to Common Terminology Criteria (CTC) for Adverse Events (AE) version 4.0 induced by these drugs.
- execution of a CT scan no earlier than 4 weeks before enrollment
- good or intermediate prognostic assessment (according to criteria of the prognostic system of the International Metastatic RCC Database Consortium)
- performance status equal or lower than 2
- blood count, hepatic and kidney testing within normal limit
- ability to give their consent to be included in the study.
Exclusion criteria:
- another known cause of diarrhea (e.g. infectious gastroenteritis. Clostridium difficile infection, celiac disease, inflammatory bowel disease, irritable bowel syndrome, chronic pancreatitis, biliary salt diarrhea)
- previous colorectal surgery or cutaneous stoma
- food allergies
- recent (<6 weeks) therapy with drugs that could possibly alter gut microbiota (e.g. antibiotics, probiotics, proton pump inhibitors, immunosuppressants, metformin)
- another cancer (except for surgically treated basocellular carcinoma)
- brain metastases
- decompensated heart failure or heart disease with ejection fraction lower than 30%
- severe respiratory insufficiency
- psychiatric disorders
- pregnancy
- unable to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Donor FMT
Fecal microbiota transplantation using stools from healthy donors
|
Fecal microbiota transplantation using stools from healthy donors
|
SHAM_COMPARATOR: Sham FMT
Sham fecal microbiota transplantation
|
Sham fecal microbiota transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of patients who experience resolution of diarrhea 4 weeks after the end of treatments
Time Frame: 4 weeks
|
rate of patients who experience resolution of diarrhea 4 weeks after the end of treatments
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of patients who need to stop or reduce treatment with tyrosine-kinase inhibitors
Time Frame: 4 weeks
|
rate of patients who need to stop or reduce treatment with tyrosine-kinase inhibitors
|
4 weeks
|
rate of patients who experience resolution of diarrhea 1 week after the end of treatments
Time Frame: 1 week
|
rate of patients who experience resolution of diarrhea 1 week after the end of treatments
|
1 week
|
rate of patients who experience resolution of diarrhea 2 weeks after the end of treatments
Time Frame: 2 weeks
|
rate of patients who experience resolution of diarrhea 2 weeks after the end of treatments
|
2 weeks
|
rate of patients who experience resolution of diarrhea 8 weeks after the end of treatments
Time Frame: 8 weeks
|
rate of patients who experience resolution of diarrhea 8 weeks after the end of treatments
|
8 weeks
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 1 week after the end of treatments
Time Frame: 1 week
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 1 week after the end of treatments
|
1 week
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 2 weeks after the end of treatments
Time Frame: 2 weeks
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 2 weeks after the end of treatments
|
2 weeks
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 4 weeks after the end of treatments
Time Frame: 4 weeks
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 4 weeks after the end of treatments
|
4 weeks
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 8 weeks after the end of treatments
Time Frame: 8 weeks
|
rate of patients who experience decrease of diarrhea until grade G1 or lower 8 weeks after the end of treatments
|
8 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMT-TKI-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Cancer
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedSorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
Case Comprehensive Cancer CenterCompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedRenal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedClear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7United States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
Clinical Trials on Donor FMT
-
University GhentUniversity Hospital, Ghent; Research Foundation Flanders; the Flanders Institute... and other collaboratorsCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEnterobacteriaceae Infections | Multi-antibiotic ResistanceItaly
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingEnterobacteriaceae Infections | Multi-antibiotic ResistanceItaly
-
Aalborg University HospitalCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
University Hospital of North NorwayThe Research Council of Norway; Umeå University; Cornell University; Quadram Institute...Completed
-
Stacy A. KahnCompletedInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisUnited States
-
University Hospital, GhentResearch Foundation FlandersRecruitingResistance BacterialBelgium
-
University Hospital, GhentCompletedIrritable Bowel SyndromeBelgium
-
Jeffrey GelfandActive, not recruitingFecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis (MS-BIOME)Relapsing Remitting Multiple SclerosisUnited States